Antibody Discovery Services

MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to membrane proteins. To provide the highest level of sensitivity, MPSA-AB5000 uses luciferase reporter cell line detection.[/caption]
MPSA-AB5000 is a high-throughput cell-based platform for identifying the targets of antibodies and other ligands that bind to membrane proteins. To provide the highest level of sensitivity, MPSA-AB5000 uses luciferase reporter cell line detection.[/caption]
The specificity of antibodies, CAR-T cells, and other biologic therapeutics to their binding targets is an important step in the evaluation process of drug development. The lack of suitable methods to identify the targets of functional antibodies and ligands result in drug safety accidents and the abandonment of previous studies.
KYinno’s Membrane Proteins Screening Array (MPSA-AB5000) is an excellent solution for antibody specificity screening which enable early off-target screening and can de-risk the antibody drug development program.
The MPSA-AB5000 platform follows a structured approach to ensure accurate target validation:
This process enables researchers to identify unintended targets early, minimizing risks before advancing to clinical development.


Our scientific team provides comprehensive support at every stage of membrane protein screening:
We work closely with research teams to ensure that each antibody candidate undergoes rigorous validation before advancing to preclinical and clinical studies.
Utilizing advanced biotechnology, our engineered bispecific antibodies bind two distinct targets. This innovation has the potential to revolutionize therapeutic strategies, heighten specificity, expand treatment options, and pave the way for future medical advancements.
Using antibodies with high specificity, Membrane Protein Antibody Discovery MPS AB5000 guarantee precise binding targets for CAR-T cells and biologics. This platform is foundational to therapeutic success and patient outcomes. Promoting next-generation healthcare solutions.
AI Drug Discovery leverages advanced algorithms to revolutionize therapeutic antibody development by streamlining the traditionally cumbersome process. Our AI-driven neural networks identify precise relationships between antibody and antigen structures, enabling the virtual generation of innovative antibody drugs.